

# Horizon Europe - Cluster Salud: Convocatorias y Novedades

5 de julio 2023, Alicante

Marta Marín, NCP y experta comité programa del Cluster Salud HE  
[marta.marin@fecyt.es](mailto:marta.marin@fecyt.es)



GOBIERNO  
DE ESPAÑA

MINISTERIO  
DE CIENCIA  
E INNOVACIÓN



INNOVACIÓN

oficina  
europea

# Oportunidades de financiación 2024: Clúster salud y otras oportunidades europeas



GOBIERNO  
DE ESPAÑA

MINISTERIO  
DE CIENCIA  
E INNOVACIÓN



oficina  
europea

# Oportunidades de financiación en Salud

## Financiación para los proyectos en salud

Horizonte Europa (DG RTD)


- Pilar I: ERC, MSCA
- Pilar II: Clúster Salud (WP, Misión Cancer, Partenariados), Otros clústers
- Pilar III: EIC, EIT
- Pilar IV: Acciones COST

EU4Health (DGSANTE, DGHERA)

DIGITAL (DGCNECT)

# Horizonte Europa

Programa marco de investigación e innovación de la Unión Europea para el período 2021 -2027 con un presupuesto de 95.517 millones de euros



# Horizonte Europa - presupuesto



# ¿Dónde encontramos la financiación para Proyectos de salud?

**Table 243. Estimated share of EU contribution covering assessed programme parts, by H2020 programme (amounts are in EUR millions)**

H2020 programme	Total analysed EU contribution (EUR millions)	EU contributions to Health Research (EUR millions)	Share % of total contribution
ERC	7 982.4	3 150.0	39 %
FET	2 517.8	1 219.4	48 %
MSCA	4074.7	1 880.1	46 %
IR	2032.6	590.7	29 %
LEITs	10 614.4	1 877.1	18 %
Access to risk finance	8.4	0.5	6 %
Innovation in SMEs	972.7	320.8	33 %
SC1	5 390.0	5 390.0	100 %
SC2	3 113.3	856.3	28 %
SC3	4 358.9	202.2	5 %
SC4	5 187.2	211.6	4 %
SC5	2 814.9	155.5	6 %
SC6	886.8	103.9	12 %
SC7	1 153.7	168.6	15 %
SEWP	642.0	281.6	44 %
SwafS	399.3	116.8	29 %
Total H2020	52 278	16 525.1	32 %

*Source: Analysis of EC administrative and monitoring data, TRR.*

# Horizonte Europa - Salud



## PILAR I CIENCIA EXCELENTE

- Proyectos bottom-up.
- Basados en investigación, objetivo aumentar la competitividad científica de la UE.



## CONSEJO EUROPEO DE INVESTIGACIÓN

Financia proyectos en la frontera del conocimiento diseñados y dirigidos por los investigadores.

Convocatorias: Starting, Consolidator, Advanced, Synergy y PoC  
[erc@fecyt.es](mailto:erc@fecyt.es)



## ACCIONES MARIE SKŁODOWSKA-CURIE (MSCA)

Apoya el desarrollo profesional y la formación del personal investigador.

Convocatorias: Doctoral Networks, Postdoctoral Fellowships, Staff Exchanges, COFUND  
[msca@fecyt.es](mailto:msca@fecyt.es)

# Horizonte Europa - Salud



## PILAR II DESAFIOS GLOBALES Y COMPETITIVIDAD INDISTRIAL

- Proyectos top-down
- Topics responden problemas y contribuyen a **políticas europeas** (European Green Deal, Economía que funciona para las personas, Estrategia digital,...)
- **Soluciones innovadoras**
- Cooperación **interdisciplinar** (incluyendo SSH), intersectorial (empresas, PYMES, centros de investigación, hospitales, pacientes/asociaciones de pacientes, agentes regulatorios, administración pública,...) e internacional (consorcios de mínimo 3 países)
- **IMPACTO** nivel social, económico, científico.

Se incluyen los Programas de trabajo, Partnerariados y Misiones.

# Horizonte Europa - Salud

## PILAR III EUROPA INNOVADORA

- Innovación que llega a mercado, apoyo a PYMES y start-ups
- Tecnologías innovadoras y disruptivas



## CONSEJO EUROPEO DE INNOVACIÓN

Ventanilla única de Horizonte Europa para todo tipo de innovadores. Convocatorias: Pathfinder, Transition, Accelerator. Convocatorias OPEN (bottom-up) o Challenges (top-down).

- [EIC Pathfinder Challenge: Precision Nutrition](#)
- [EIC Transition Challenge: Full scale Micro-Nano-Bio devices for medical and medical research applications](#)
- [EIC Accelerator Challenge: Novel biomarker-based assays to guide personalised cancer treatment](#)



## EIT-HEALTH

Impulsa la innovación mediante la integración de los centros de educación, las empresas y los centros de investigación para encontrar soluciones a los retos mundiales acuciantes. Centrado en la formación de emprendedores.

# Horizonte Europa - Salud

WIDENING PARTICIPATION AND STRENGTHENING THE EUROPEAN RESEARCH AREA

Widening participation & spreading excellence

Reforming & Enhancing the European R&I system

## PILAR IV AMPLIAR LA PARTICIPACIÓN Y FORTALECER EL ESPACIO EUROPEO DE INVESTIGACIÓN


- Apoya la diversidad geográfica
- Promueve redes de contactos y acceso a la excelencia para mejorar la participación en pilar II y III



### ACCIONES COST


Redes interdisciplinares internacionales, que permiten establecer consorcios.  
Financian reuniones, training, actividades de comunicación.

# Horizonte Europa



# Horizonte Europa – Strategic plan 2021-2024

## Intervention logic of Cluster 1 ‘Health’



# Horizonte Europa – Destinos



Mantenerse sano en una sociedad que cambia rápidamente

Vivir y trabajar en un ambiente que promueva la salud

Hacer frente a las enfermedades y reducir la carga de la enfermedad

Garantizar el acceso a una atención sanitaria innovadora, sostenible y de alta calidad

Desplegando todo el potencial de las nuevas herramientas, tecnologías y soluciones digitales para una sociedad sana

Mantener una industria de la salud innovadora, sostenible y competitiva a nivel mundial

# Clúster Salud

Clúster  
Salud  
8.246M€




# Clúster Salud – WP 2024

15 topics

55 Proyectos  
financiados

509 M€  
contribución  
CE

- **1 partenariado** – One Health Anti-Microbial Resistance
- **5 topics single stage**
  -  11 de Abril 2024
- **9 topics two-stage**
  -  19 de Septiembre 2023 (1ª fase), 11 Abril 2024 (2ª fase)
  -  Blind evaluation 1ª fase
  -  Costes lump sum

## Destination 1 - Mantenerse sano en una sociedad que cambia rápidamente

Topic	Type of Action	Budget	Budget/proposal	Deadlines	Procedure	Costs
<b>HORIZON-HLTH-2024-STAYHLTH-01-02- two-stage:</b> Towards a holistic support to children and adolescents' health and care provisions in an increasingly digital society.	RIA	30M€	8-10M€/prop 3 propuestas	19/09/2023 11/04/2024	Blind evaluation	Lump sum
<b>HORIZON-HLTH-2024-STAYHLTH-01-05- two-stage:</b> Personalised prevention of noncommunicable diseases - addressing areas of unmet needs using multiple data sources.	RIA	50M€	8-12M€/prop 5 propuestas	19/09/2023 11/04/2024	Blind evaluation	Lump sum

## Destination 2 - Vivir y trabajar en un ambiente que promueva la salud

Topic	Type of Action	Budget	Budget/proposal	Deadlines	Procedure	Costs
<b>HORIZON-HLTH-2024-ENVHLTH-02-06-two-stage:</b> The role of environmental pollution in non-communicable diseases: air, noise and light and hazardous waste pollution	RIA	60M€	7-8M€/prop 8 propuestas	19/09/2023 11/04/2024	Blind evaluation	Lump sum

## Destination 3 - Hacer frente a las enfermedades y reducir la carga de la enfermedad

Topic	Type of Action	Budget	Budget/proposal	Deadlines	Procedure	Costs
<b>HORIZON-HLTH-2024-DISEASE-03-08-two-stage:</b> Comparative effectiveness research for healthcare interventions in areas of high public health need	RIA	45M€	6-7M€/prop 7 propuestas	19/09/2023 11/04/2024	Blind evaluation	Lump sum
<b>HORIZON-HLTH-2024-DISEASE-03-11-two-stage:</b> Pandemic preparedness and response: Adaptive platform trials for pandemic preparedness	RIA	30M€	8-10M€/prop 3 propuestas	19/09/2023 11/04/2024	Blind evaluation	Lump sum
<b>HORIZON-HLTH-2024-DISEASE-03-13-two-stage:</b> Validation of fluid-derived biomarkers for the prediction and prevention of brain disorders	RIA	25M€	6-8M€/prop 3 propuestas	19/09/2023 11/04/2024	Blind evaluation	Lump sum
<b>HORIZON-HLTH-2024-DISEASE-03-14-two-stage:</b> Tackling high-burden for patients, under-researched medical conditions	RIA	24M€	6-7M€/prop 4 propuestas	19/09/2023 11/04/2024	Blind evaluation	Lump sum
<b>HORIZON-HLTH-2024-DISEASE-08-12:</b> Pandemic preparedness and response: Maintaining the European partnership for pandemic preparedness	CSA	2M€	2M€/prop 1 propuestas	11/04/2024		Actual costs
<b>HORIZON-HLTH-2024-DISEASE-08-20:</b> Pandemic preparedness and response: Host-pathogen interactions of infectious diseases with epidemic potential	RIA	50M€	7-8M€/prop 5 propuestas	11/04/2024		Actual costs

## Destination 4 - Garantizar el acceso a una atención sanitaria innovadora, sostenible y de alta calidad

Topic	Type of Action	Budget	Budget/proposal	Deadlines	Procedure	Costs
<b>HORIZON-HLTH-2024-CARE-04-04-two-stage:</b> Access to health and care services for people in vulnerable situations	RIA	30M€	4-6M€/prop 5 propuestas	19/09/2023 11/04/2024	Blind evaluation	Lump sum

## Destination 5 - Desplegando todo el potencial de las nuevas herramientas, tecnologías y soluciones digitales para una sociedad sana

Topic	Type of Action	Budget	Budget/proposal	Deadlines	Procedure	Costs
<b>HORIZON-HLTH-2024-TOOL-05-06-two-stage:</b> Innovative non-animal human-based tools and strategies for biomedical research	RIA	25M€	4-8M€/prop 4 propuestas	19/09/2023 11/04/2024	Blind evaluation	Lump sum
<b>HORIZON-HLTH-2024-TOOL-11-02:</b> Bio-printing of living cells for regenerative medicine	RIA	25M€	6-8M€/prop 4 propuestas	11/04/2024		Actual costs

## Destination 6 - Mantener una industria de la salud innovadora, sostenible y competitiva a nivel mundial

Topic	Type of Action	Budget	Budget/proposal	Deadlines	Procedure	Costs
<b>HORIZON-HLTH-2024-IND-06-08:</b> Developing EU methodological frameworks for clinical/performance evaluation and post-market clinical/performance follow-up of medical devices and in vitro diagnostic medical devices (IVDs)	RIA	10M€	8-10M€/prop 1 propuestas	11/04/2024		Actual costs
<b>HORIZON-HLTH-2024-IND-06-09:</b> Gaining experience and confidence in New Approach Methodologies (NAM) for regulatory safety and efficacy testing – coordinated training and experience exchange for regulators	CSA	2M€	2M€/prop 1 propuestas	11/04/2024		Actual costs

# Clúster Salud – más información



# Misión Cancer

Las misiones son una manera de dar **soluciones concretas a grandes retos de la Sociedad**. Tiene objetivos ambiciosos y se espera obtener resultados concretos para 2030.

## FIVE MISSIONS

Missions have ambitious goals and will deliver concrete results by 2030.



**cancer:** improve the lives of more than 3 million people



make 150 regions and communities **climate resilient**



restore our **ocean and waters**



achieve 100 **climate-neutral and smart cities**



create 100 living labs and lighthouses to lead the transition towards **healthy soils**

## ROOTED IN RESEARCH AND INNOVATION

Part of the Horizon Europe research and innovation programme, **missions stem from research and innovation and aim for more!**

Horizon Europe provides initial funding of up to **€1.9 billion** for the first three years.

**Missions will directly support the EU priorities:**


- European Green Deal
- New European Bauhaus
- Europe fit for the Digital Age
- Europe's Beating Cancer Plan
- An Economy that Works for People
- EU's Long-term Vision for Rural Areas



# Misión Cáncer

WP anuales, topics 2024 TBP

1- Understanding Cancer, 2- Prevention and early detection, 3- Diagnosis and treatment , 4- Improving quality of life



# Partenariados en Horizonte Europa

Agrupaciones transnacionales de entidades públicas y/o privadas con capacidades técnicas y financieras necesarias para afrontar grandes desafíos.

Facilitan:

- Comprometer gran volumen de fondos
- Crear sinergias con la financiación nacional, regional o privada
- Poner en marcha planes de financiación diseñados conjuntamente con entidades del sector objetivo
- Establecer estructuras de gestión más ágiles y operativas

## The Partnerships' solutions include:

tackle antimicrobial resistance



understand health determinants, disease areas

strengthen pandemic preparedness



better protection from chemical risk



personalised medicine



new and improved health technologies

people-centred, integrated health-care



address Infectious diseases in Sub-Saharan Africa

better diagnosis and treatment of rare diseases

# Partenariados en Horizonte Europa

H2020



EuroNanoMed3



HORIZONTE EUROPA

Innovative Health Initiative

Global Health EDCTP3

Transformation of Health Care Systems

Risk Assessment of Chemicals (PARC)

ERA for Health

Personalised Medicine

Rare Diseases

One-Health AMR

Pandemic Preparedness (BE READY)?

Brain Research

Institutionalised partnership (*F&T portal*)




Co-funded partnership (*web propia*)

Co-programmed (*WP Salud*)

# Partenariados en salud

 TRANSCAN	TRANSCAN-3	JTC-2023 pre-proposal 21/07/2023	cbarco@isciii.es, transcan@ficyt.es, AECC
	EJP-RD	JTC 2023 closed	mauriciog@isciii.es
 innovative health initiative	Innovative Health Initiative	IHI-4 y 5 call (drafts published)	marta.dediego@cdti.es
	Global Health EDCTP3	HORIZON-JU-GH-EDCTP3-2023-01 (4 RIA, 1 CSA) closed HORIZON-JU-GH-EDCTP3-2023-02-two-stage (2 RIA): 28/09/2023	tlpena@isciii.es
	Transformation of HealthCare Systems	JTC 2023 closed	IDIVAL, CSCJA, BIOEF, ISCIII
	ERA for Health	CARDINNOV, HealthEquity calls closed	AEI, ISCIII, CSCJA
	Risk Assessment of Chemicals	Calls to be launched	ISCIII, CSIC

# No sólo en HE hay financiación para proyectos en salud...



# Otros programas - EU4HEALTH

Programa de salud enfocado en la implementación

WP anuales

Formas de participación:

- **Joint Actions:** los EEMM son los que participan mediante la nominación de 1 entidad que participa como Competent Body para esa JA concreta.
- **Action Grants:** propuestas que responden a topics que contribuyen a los objetivos de EU4Health.
- **Operating grants:** grants financia a entidades concretas (costes operacionales) a entidades que contribuyen a los objetivos de EU4Health
- **Procurement:** adquisición de un servicio por parte de la CE.



▪ Improve & foster health in the Union



▪ Protect people from serious cross-border health threats



▪ Improve access to medicinal products, medical devices, crisis-relevant products



▪ Strengthen health systems

# Otros programas - EU4HEALTH

## EU4Health 2023 Work Programme

<b>1. CRISIS PREPAREDNESS (CP)</b>		<b>358.40</b>
HERA <sup>16</sup>		242.75
IMPROVING AND STRENGTHENING NATIONAL SURVEILLANCE SYSTEMS		97.6
STRENGTHENING THE EU EARLY WARNING AND RESPONSE SYSTEM AND NATIONAL ALERT AND INFORMATION SYSTEMS (EWRS) <sup>17</sup>		2.0
EUROPEAN IMMUNIZATION AGENDA <sup>18</sup>		2.0
SUPPORT THE SET-UP ESTABLISHMENT AND OPERATION OF EU REFERENCE LABORATORIES		8.2
ADVISORY COMMITTEE SET - UP TO DEAL WITH EMERGENCIES		0.45
RISK ASSESSMENTS FOR CHEMICAL, ENVIRONMENTAL AND CLIMATE THREATS DRAWN UP WITHIN AGENCIES <sup>19</sup>		0.6
INTEGRATED SURVEILLANCE SYSTEMS ON ANTIMICROBIAL RESISTANCE AND ANTIMICROBIAL USE		0.5
CRISIS PREPAREDNESS IN UKRAINE AND NEIGHBOURING COUNTRIES <sup>20</sup>		4.3
<b>2. HEALTH PROMOTION &amp; DISEASE PREVENTION (DP)</b>		<b>33.54</b>
TOBACCO CONTROL POLICIES		4.0
PREVENTION OF NON-COMMUNICABLE DISEASES (NCDs) – CHRONIC RESPIRATORY DISEASES, MENTAL HEALTH, DEMENTIA		18.36
OPERATING GRANTS		9.0
SUPPORT TO HEALTH POLICY PLATFORM, SCIENTIFIC COMMITTEES, AND EXPERT GROUPS, AND SUPPORT TO EUROPEAN CLIMATE AND HEALTH OBSERVATORY		2.18
<b>5. DIGITAL (DI)</b>		<b>26.0</b>
EUROPEAN HEALTH DATA SPACE – INFRASTRUCTURE AND GOVERNANCE; PRIMARY USE OF DATA		19.5
EUROPEAN HEALTH DATA SPACE – INFRASTRUCTURE AND GOVERNANCE; SECONDARY USE OF DATA		6.5
<b>3. CANCER (CR)</b>		<b>187.3</b>
CANCER PREVENTION		1.5
EU NETWORK OF COMPREHENSIVE CANCER INFRASTRUCTURES		130.5
IMPLEMENTATION OF CANCER SCREENING PROGRAMMES		38.5
MENTAL HEALTH AND CANCER		10.0
QUALITY OF LIFE OF CANCER SURVIVORS		1.5
REDUCING CANCER INEQUALITIES <sup>21</sup>		2.5
IMPLEMENTATION OF STRATEGIC AGENDA FOR MEDICAL IONISING RADIATION		2.8
<b>4. HEALTH SYSTEMS &amp; HEALTHCARE WORKFORCE (HS)</b>		<b>118.42</b>
REFORMING AND STRENGTHENING HEALTH SYSTEMS <sup>22</sup>		8.7
ENHANCING EUROPEAN REFERENCE NETWORKS		83.4
STRENGTHENING THE IMPLEMENTATION OF THE LEGISLATION ON BLOOD, TISSUES AND CELLS AND ORGANS		1.4
IMPLEMENTATION OF REGULATIONS ON MEDICAL DEVICES AND IN VITRO DIAGNOSTIC MEDICAL DEVICES		8.25
IMPLEMENTATION OF PHARMACEUTICALS LEGISLATION AND PHARMACEUTICAL STRATEGY FOR EUROPE <sup>23</sup>		8.17
IMPLEMENTATION OF THE HEALTH TECHNOLOGY ASSESSMENT REGULATION		3.00
IMPLEMENTATION OF THE CROSS-BORDER HEALTHCARE DIRECTIVE		0.5
GLOBAL HEALTH		5.0
<b>6. OTHER ACTIONS</b>		<b>12.12</b>
COMMUNICATION ACTIVITIES		3.67
RECURRENT IT ACTIVITIES		5.5
OTHER ACTIVITIES		2.95




# Otros programas - DIGITAL

El programa **Digital Europe Programme** se centra en implementar tecnologías digitales en negocios, administración pública y para los ciudadanos.

## Funding schemes

- Grants with 50% funding rate (75% possible for SMEs)
- CSA at 100%
- Wide use of procurement

La mayoría de Topics en [Funding and Tenders](#)



## DIGITAL and HEALTH

### Cloud, Data and AI

- 2024: Federated European Infrastructure for Intensive Care Units' (ICU) data
- 2024: Genome of Europe
- 2024: Platform for advanced virtual human twin (VHT) models
- **Data Spaces – Genomics (GDI), Cancer Images (EUCAIM)**

### Cybersecurity

- Support to cybersecurity in the health sector

### Deployment and Best Practices

- Uptake of digital solutions in Health and Care
- An ecosystem for digital twins in healthcare (EDITH)

### Advanced digital skills

# Introducción a los conceptos BLIND EVALUATION y LUMP SUM



GOBIERNO  
DE ESPAÑA

MINISTERIO  
DE CIENCIA  
E INNOVACIÓN



oficina  
europea

# Novedades en topics 2024

**HORIZON-HLTH-2024-STAYHLTH-01-05-two-stage: Personalised prevention of non-communicable diseases - addressing areas of unmet needs using multiple data sources**

Specific conditions	
<i>Procedure</i>	<p>The procedure is described in General Annex F. The following exceptions apply:</p> <p>This topic is part of the <b>blind evaluation pilot</b> under which first stage proposals will be evaluated blindly.</p>
<i>Legal and financial set-up of the Grant Agreements</i>	<p>The rules are described in General Annex G. The following exceptions apply:</p> <p><b>Eligible costs will take the form of a lump sum</b> as defined in the Decision of 7 July 2021 authorising the use of lump sum contributions under the Horizon Europe Programme – the Framework Programme for Research and Innovation (2021-2027) – and in actions under the Research and Training Programme of the European Atomic Energy Community (2021-2025).<sup>40</sup>.</p>

Topics de 2 fases:

- **Blind evaluation** en la primera fase
- **Lump sum** en la segunda fase

# Blind Evaluation

With this pilot we want to tackle some understandable concerns that the evaluation process could be **perceived as biased towards well-known organisations in countries with better performing Research and Innovation systems**



**NEW admissibility criterion:** Applicants submitting a proposal under the blind evaluation pilot must not disclose their **organisation names, acronyms, logos nor names of personnel** in Part B of their first-stage application.

**Part A** - Will not be transmitted to evaluators (complete as usual)

**Part B** - If proposals include any identification of the applicant in Part B, the proposal will be declared **inadmissible and will be rejected**.




No identification data can be mentioned by applicants in the proposal's **Part B**, otherwise **inadmissible proposal**

# Blind Evaluation

- ✓ It will be launched in the WP 2023-24
- ✓ All two-stage calls in 2023 and 2024 should take part in the pilot (except justified cases)
- ✓ It will only concern the **first stage application** of two-stage calls (only EXCELLENCE AND IMPACT are evaluated)
- ✓ The pilot aims to identify whether the **implementation of blind evaluation** within our legal requirements and operational context creates any difficulties. If this is not the case, it might lead to a modified approach, with a greater use of blind evaluations, which could effectively mitigate the risk of real, potential or perceived reputational bias.
- ✓ We expect that there will be admissible proposals where the evaluator could guess the identity of the applicant regardless (e.g., small research community). We plan to track those cases and examine **to what extent true blind evaluations were possible.**

- No identification of partners – ADMISSIBLE -> Evaluation
- Indirect identification or Grey-zone cases --> CASE BY CASE study (admissible/inadmissible, intentionally assessed)
- Direct identification of partners – INADMISSIBLE (intentionally assessed) -> Rejected

# Blind Evaluation - proceso



## Proposal submission

**Part A** - complete as usual

**Part B** – avoid disclosing organizational names, acronyms, logo nor name of personnel. Proposals with blacked out names and information are not preferred but accepted.

## Guidance for blind evaluations

Proposals submitted to a call taking part in the blind evaluation pilot must be anonymous: proposals may not contain any direct or indirect reference to the organisations or persons participating in the proposals. This means that participants **must not disclose** applicants' organisation names, acronyms, logos nor names of personnel in the Part B of the application (the narrative uploaded as a pdf document). In addition, names of proposers or their organisations should not be potentially identifiable indirectly, via, for instance, links to web pages or through references to their role and previous experience.

The proposal can include references to their own publications if there is no emphasis that the publication is authored by one or more of the proposers.

The proposal will be declared inadmissible if its anonymity is not respected in the part B of the application. Information on the identity of participants should be included **only** in proposal Part A (the structured online web forms).

### How to insert references to publications

The proposal can include references to participants' own publications if there is no emphasis that the publication is authored by one or more of the proposers.

For example, the following statement will not be admissible:


*'For climate impact, we will use greenhouse gas emission intensities, following a methodology developed previously by a project partner (Dalin et al.)'*  
but the following would be ok:

*'For climate impact, we will use greenhouse gas emission intensities, following the methodology described in Dalin et al.'*

### Examples of statements resulting in inadmissible proposals


- 'Most of project's participants have been involved in the previous H2020 project, NANOCOM..'
- 'For climate impact, we will use greenhouse gas emission intensities, following a methodology developed previously by a project partner (Dalin et al.)'
- 'This task in WP3 will be based on outputs generated by some participants of the consortium', (with a link in the footnote to a YouTube video or webpage where participants can be identified)
- 'The consortium includes the largest research institute in France'
- 'Partner 3 is the leading company in Spain for wind turbine installation'
- 'Our current research expands our previous findings described in a recently published article (Wiliam et al, 2022)'
- 'The consortium consists of leaders in the high tech industry, including the biggest in terms of capital constructor of micro chips'
- 'The coordinator organisation was the one who first introduced the concept of m-RNA in vaccines'
- 'The consortium consists of 2 research centres (including an international one based in Geneva) and the oldest university in Belgium'

# Blind Evaluation - proceso



**NEW Admissibility criterion:** Organisation names, acronyms, logos or names of personnel should not appear in Part B


# Blind Evaluation - proceso



## Guidance for evaluators

- ✓ Should Experts notice any direct or indirect identification of the applicant, they should notify the staff officer.
- ✓ Experts should evaluate the proposal blindly, without taking extra steps to investigate based on the information included in the proposal, who is behind the project.
- ✓ Listing R&I activities, including on-going or finished projects, does not necessarily entail that the applicants are also participants of those mentioned activities.
- ✓ The proposal can include references to participants' own publications if there is no emphasis that the publication is authored by one or more of the proposers.
- ✓ Names of past projects can be mentioned, but it cannot be explicitly indicated that the proposal is a continuation of these projects or that the partners from the past projects overlap with project partners of the current proposal.
- ✓ The name of the city and its characteristics can be mentioned, provided that there is no explicit indication in the proposal, that any of the applicants are from this location (even if this would be in reality the case). Otherwise, if the participant wants to mention that one of project partners is coming from/ is closely connected with the given city, then the city name should not be mentioned and the city should be only vaguely described by its characteristics, which would not allow for its identification

# Blind Evaluation - proceso



## Evaluation form



### Assessment of the pilot on Blind Evaluation

- Experts evaluators are asked in one **additional question** whether they were **able to guess the identity of the applicants (at least one)** behind the proposal, even if the proposal was **fully admissible** because it did not contain any direct or indirect reference to the identity of the participants.
- Should the answer to this question be 'yes', Experts are asked to provide their guess who the applicant(s) is.
- The purpose of this question is to measure whether true blind evaluations are possible given the operational and legal context of the Horizon Europe evaluation procedure. The feedback from the Experts will contribute to the assessment of the pilot on Blind Evaluations.
- Experts should not share and discuss their guesses regarding the identity of the applicant(s) among each other.

#### Assessment of the pilot on Blind Evaluation

Were you able to guess the identity of the applicants (at least one) behind the proposal, even if the proposal was fully admissible because it did not contain any direct or indirect reference to the identity of the participants?

- No  
 Yes

If YES, could you provide us with your guess who the applicant(s) is?

[Comment box]

# Blind Evaluation – Referencias neutrales



PUBLICACIONES	For climate impact, we will use greenhouse gas emission intensities, following a methodology developed previously <u>by a project partner</u> (Dalin et al.)	'For climate impact, we will use greenhouse gas emission intensities, following the methodology described in Dalin et al.'
PROJECT	'Most of project's <u>participants have been involved in the previous</u> H2020 project, NANOCOM...'	The project is based on results from a h2020 project, NANOCOM
COHORTS	The project will count with data from the <u>Spanish CoRIS cohort</u>	The project will count with data from a large VIH cohort.
PAISES	The consortium includes <u>the largest</u> research institute in France	The consortium includes a (large) research institute in France
EXPERTISE	'Partner 3 is <u>the leading company in Spain</u> for wind turbine installation'	'Partner 3 is a leading company in Spain for wind turbine installation' (if there are 10 companies) 'Partner 3 is a company for wind turbine installation'

# Blind Evaluation – más información

Info Session for NCPs: Special webinar on blind evaluations in Horizon Europe  
(28 February 2023)

28 FEB 2023	15.00 - 17.00 CET (BRUSSELS TIME)
Info Session for NCPs: Special webinar on blind evaluations in Horizon Europe	
15:00	Introduction and presentation Izabela PROKOPOWICZ (RTD.H3) [ <a href="#">presentation</a> ]
15:30	Q&A
17:00	End of the meeting

## HORIZON EUROPE PROPOSAL EVALUATION

### PILOT ON BLIND EVALUATION



**Guidance for blind evaluations**

Proposals submitted to a call taking part in the blind evaluation pilot must be anonymous: proposals may not contain any direct or indirect reference to the organisations or persons participating in the proposals. This means that participants **must not disclose** applicants' organisation names, acronyms, logos nor names of personnel in the Part B of the application (the narrative uploaded as a pdf document). In addition, names of proposers or their organisations should not be potentially identifiable indirectly, via, for instance, links to web pages or through references to their role and previous experience.

The proposal can include references to their own publications if there is no emphasis that the publication is authored by one or more of the proposers.

The proposal will be declared inadmissible if its anonymity is not respected in the part B of the application. Information on the identity of participants should be included **only** in proposal Part A (the structured online web forms).

**How to insert references to publications**

The proposal can include references to participants' own publications if there is no emphasis that the publication is authored by one or more of the proposers.

For example, the following statement will not be admissible:

*'For climate impact, we will use greenhouse gas emission intensities, following a methodology developed previously by a project partner (Dalin et al.)'*

but the following would be ok:

*'For climate impact, we will use greenhouse gas emission intensities, following the methodology described in Dalin et al.'*

**Examples of statements resulting in inadmissible proposals**

- 'Most of project's participants have been involved in the previous H2020 project, NANOCOM...'
- 'For climate impact, we will use greenhouse gas emission intensities, following a methodology developed previously by a project partner (Dalin et al.)'
- 'This task in WP3 will be based on outputs generated by some participants of the consortium', (with a link in the footnote to a YouTube video or webpage where participants can be identified)
- 'The consortium includes the largest research institute in France'
- 'Partner 3 is the leading company in Spain for wind turbine installation'
- 'Our current research expands our previous findings described in a recently published article (Wiliam et al, 2022)'
- 'The consortium consists of leaders in the high tech industry, including the biggest in terms of capital constructor of micro chips'
- 'The coordinator organisation was the one who first introduced the concept of m-RNA in vaccines'
- 'The consortium consists of 2 research centres (including an international one based in Geneva) and the oldest university in Belgium'



## COST Open Call – Applicant Guidelines (Submission, Evaluation, Selection and Approval - SESA) - Level C


November 2022

Open Call oc-2023-1

COST 104/21  
V2.0

# Lump Sum

- ✓ Financiación en base a **cantidades a tanto alzado por Work Packages (WP)** fijadas al inicio del proyecto en lugar de un reembolso en base a costes incurridos.
- ✓ El pago se hace en base la **REALIZACIÓN DE WP** y no en base a los resultados o costes incurridos. **Elimina todas las obligaciones de reporting financiero** (i.e. reducción de la carga administrativa), reporting únicamente técnico.
- ✓ Importante la definición de WP (en relación a los reporting periods) y responsabilidades de cada socio.



PREPARACIÓN  
DE  
PROUESTA!!

# Lump Sum

Call: [insert call identifier] – [insert call name]

EU Grants: Application form (HE 1<sup>st</sup> stage RIA and IA): V3.5 – 25.04.2023

**Proposal template Part B: technical description**

**TITLE OF THE PROPOSAL**

This document is tagged. Do not delete the tags; they are needed for processing.] @@APP-FORM-HERIAIA1ST@@ #@@REL-EVA-RE@#

**1. Excellence**

**1.1 Objectives and ambition** @@PRI-OBJ-PO@#

Insert here text for your proposal

#\$PRI-OBJ-PO\$#

**1.2 Methodology** @@CON-MET-CM@# @@COM-PLE-CP@#

Insert here text for your proposal

#\$CON-MET-CM\$# #\$COM-PLE-CP\$# #\$REL-EVA-RE\$#

**2. Impact** @@IMP-ACT-IA@#

**2.1 Project's pathways towards impact**

Insert here text for your proposal

#\$IMP-ACT-IA\$#

Part B - Page 1 of [Page limit]

Example, not to complete

# Lump Sum

Call: [insert call identifier] – [insert call name]

EU Grants: Application form (HE 1<sup>st</sup> stage RIA and IA): V3.5 – 25.04.2023

**Proposal template Part B: technical description**

**TITLE OF THE PROPOSAL**

This document is tagged. Do not delete the tags; they are needed for processing.] @@APP-FORM-HERIAIA1ST@# @@REL-EVA-RE@#

**1. Excellence**

**1.1 Objectives and ambition** @@PRI-OBJ-PO@#

Insert here text for your proposal

#\$PRI-OBJ-PO\$#

**1.2 Methodology** @@CON-MET-CM@# @@COM-PLE-CP@#

Insert here text for your proposal

#\$CON-MET-CM\$# #\$COM-PLE-CP\$# #\$REL-EVA-RE\$#

**2. Impact** @@IMP-ACT-IA@#

**2.1 Project's pathways towards impact**

Insert here text for your proposal

#\$IMP-ACT-IA\$#

Part B - Page 1 of [Page limit]

BUT...

Application Forms

Proposal ID XXXXXXXX Acronym XXXXXX Participant short name: XXXX

**3 – Budget for the proposal**

**TOTAL Requested EU contribution to eligible costs (Requested grant amount) - EUR**

Version of template used Page 9 of 9 Last saved dd/mm/yyyy HH:mm

This proposal version was submitted by [Name, FAMILY NAME] on [dd/mm/yyyy HH:mm:ss] Brussels Local Time. Issued by the Funding and Tenders Portal Submission Service.

# Lump Sum - propuesta

## Templates (en 2a fase)

1. Plantillas estándar de Horizonte Europa – [límite extendido para lump sum a 50pags RIAs](#)
2. Anexo presupuestario LS (Detailed Budget table – Excel)

## ¿Cómo diseñar el plan de trabajo?

Definición: “*Work package means a major sub-division of the work plan of your project*”

- Una sola actividad NO es un work package
  - Una sola tarea NO es un work package
  - Un % de progreso/realización NO es un work package
  - Un lapso de tiempo NO es un work package
-  As many as needed but no more than what is manageable
- 
- **Regla general:** diseñar el plan de trabajo y definir los WP de manera similar a un proyecto basado en costes reales (actual costs)
  - **WP Transversales** (i.e. Gestión, Comunicación+Difusión+Explotación, **EECC**): se pueden dividir entre los diferentes periodos de justificación, normalmente cada 18m.
  - Dedicar tiempo y esfuerzo para asegurar que el plan de trabajo tiene sentido y la **distribución de WP permite mantener un cashflow adecuado**.

# Lump Sum – tips para propuestas

- Los pagos se realizan cuando **todas las actividades del WP** se han completado
- El pago **no depende de resultados positivos**, sino de haber completado el WP
- Se aceptará un WP en el que se han completado las tareas esenciales y otras equivalentes se han llevado a cabo o hay desviaciones si está justificado
- La **descripción de los WP y los deliverables debe ser (más) precisa**
- Debe quedar claro dentro de cada WP cuál es la contribución exacta de cada socio
- Se pueden hacer **enmiendas para modificar la descripción técnica de los WP**. De hecho, se indica que se deben hacer enmiendas de acuerdo a necesidades científico técnicas para asegurarse que se completan los WP.
- Si un PO nos rechaza el WP como completado, podemos responder a las observaciones del Officer
- Los **WP transversales o largos se pueden fragmentar**. No debemos tener numerosos WP pero algo como 2X sería aceptable.
- El número de WP se va a incrementar, pero no el número de deliverables!!
- Cuando subdividimos WP no es necesario volver a repetir la descripción del WP.

# Lump Sum – más información



**Jornada informativa Horizon Europe:  
aspectos en evolución (participación de  
las fundaciones hospitalarias, lump  
sums y blind evaluation)**

14 de Junio de 2023

El próximo día 14 de junio se celebra la jornada "Horizon Europe: aspectos en evolución (participación de las fundaciones hospitalarias, lump sums y blind evaluation)".

Jornada Nacional sobre el modelo de acuerdo de subvención Lump Sum en Horizonte Europa

Agenda Registro

Junio 29

Comienza: 10:30

Jornada híbrida

Funding & tender opportunities

Single Electronic Data Interchange Area (SEDIA)

English EN

Register Login

Get started

Lump sum funding in Horizon Europe

This page brings together all information on lump sum funding in Horizon Europe. It is updated regularly to provide the latest state of play.

Horizon Europe uses lump sum funding to **reduce administration and financial errors**. Lump sums make the programme simpler by removing the need to report actual costs. This means **easier access to the programme**, especially for small organisations and newcomers, who often lack the experience and capacity to cope with the complex rules for actual costs.

Lump sums are **defined up-front** and fixed in the grant agreement. They are **paid upon completion of the activities in work packages**.

Beyond that, the planning, evaluation, and execution of projects does not change much. In particular, the payment of lump sums is **not dependent on successful outcomes** (which are never certain in research) and follows the **standard payment schedule**. Lump sum projects enjoy the **same degree of flexibility**, and their performance is **judged by the same standards**.

# Aspectos claves en la preparación de una propuesta Horizonte Europa



GOBIERNO  
DE ESPAÑA

MINISTERIO  
DE CIENCIA  
E INNOVACIÓN



oficina  
europea

# Cómo preparar una propuesta

## GENERACIÓN DE IDEAS



## FORMACIÓN DEL CONSORCIO



- ✓ Contribuye a algún problema o necesidad a nivel europeo.
- ✓ Requiere colaboración europea.
- ✓ Tiene **impacto** a nivel social, económico, científico.
- ✓ Da respuesta a topics, destinos WP y contribuye a las prioridades de las CE y los ODS.
- ✓ Tipo de propuesta:
  - RIA – investigación
  - IA – innovación
  - CSA – colaboración
  
- ✓ Mínimo de una entidad de un EEMM + dos entidades de EEMM o países asociados (*condición de elegibilidad*)
  - UK entities: participan como beneficiarios, en el momento de firma de GA se cambian/no a associated partners y reciben fondos/no (según disponibilidad en fondo de garantía UKRI).
- ✓ Las entidades públicas, organismos de investigación o de educación superior deben tener un **Plan de Igualdad de Género** (*condición de elegibilidad*)

# Cómo preparar una propuesta

## ELABORACIÓN PROPUESTA



## PRESENTACIÓN PROPUESTA



**Parte A - formularios online.** Información general sobre la propuesta, los socios, desglose presupuestario e información sobre aspectos éticos.

**Parte B - memoria técnica del proyecto.** Se estructura en las secciones de excelencia, impacto e implementación.

- ✓ Se debe incluir un Plan de difusión, comunicación explotación de los resultados (*Condición de admisibilidad*).
- ✓ Se tienen en cuenta los aspectos transversales: ética e integridad, seguridad y protección de datos, inclusividad, perspectiva de género, ciencia abierta, respeto al entorno, etc.
- ✓ Se recomienda incluir un anexo específico para EECC, si aplica (1 anexo/propuesta, tantos EECC como sean necesario!).
- ✓ **Ciencia Abierta** incluida en la parte de excelencia y implementación. Acceso abierto a publicaciones y datos.

- ✓ La propuesta debe ser completa, legible, accesible e imprimible (*Condición de admisibilidad*).

- ✓ La propuesta no debe exceder los **límites máximos de extensión** (salvo excepciones) (*Condición de admisibilidad*):

1st stage: 10 págs

2nd stage-lump sum: 50 págs. para RIAs e IAs, 33 págs. para CSA

single stage: 45 págs. para RIAs e IAs, 30 págs. para CSA

- ✓ La propuesta se debe de presentar antes del fin de plazo (*Condición de admisibilidad*): 1st stage 19/09/2023, 2nd stage y single stage: 11/04/2024

# Cómo preparar una propuesta

## EVALUACIÓN PROPIUESTA



## SOPORTE



- ✓ Los criterios de evaluación son: excelencia, impacto, calidad y eficiencia en la implementación.
- ✓ Para optar a conseguir financiación, se deben superar los siguientes **umbrales de puntuación**: como mínimo 4/5 en las secciones de excelencia e impacto, 3/5 en la sección de implementación y una puntuación total mínima de 12/15.



Marta Marín  
FECYT, MCIN  
[marta.marin@fecyt.es](mailto:marta.marin@fecyt.es)  
+34 91 425 09 09



Carolina Carrasco  
CDTI  
[carolina.carrasco@cdti.es](mailto:carolina.carrasco@cdti.es)  
+34 91 581 55 62



Marta de Diego  
CDTI  
[marta.dediego@cdti.es](mailto:marta.dediego@cdti.es)  
+34 91 581 55 62



Gustavo García  
NCP Asuntos Legales y Financieros  
[gustavo.garcia@fecyt.es](mailto:gustavo.garcia@fecyt.es)  
+34 91 425 09 09



Mª Carmen Bello  
NCP Asuntos Legales y Financieros  
[carmen.bello@fecyt.es](mailto:carmen.bello@fecyt.es)  
91 425 09 09

# Excelencia

**Proposal template Part B: technical description**

TITLE OF THE PROPOSAL		
[This document is tagged. Do not delete the tags; they are needed for processing.] #@APP-FORM-HERIAIA#@		
<b>List of participants</b>		
Participant No. *	Participant organisation name	Country
1 (Coordinator)		
2		
3		
...		

1. **Excellence** #@REL-EVA-RE#@  
1.1 **Objectives and ambition** #@PRJ-OBJ-PO#@

Insert here text for your proposal

#\$PRJ-OBJ-PO\$#


1.2 **Methodology** #@CON-MET-CM#@ #COM-PLE-DR#@

Insert here text for your proposal

#\$CON-MET-CM\$# #\$COM-PLE-DR\$# #\$REL-EVA-RE\$#

## Objectives and amition

- Objetivos SMART *Specific – Measurable – Achievable – Relevant – Time-bound*



- Trazabilidad de los objetivos Objetivo – impacto – métricas – WP
- SoA + en qué/cómo avanzamos el SoA
- Análisis de la “competencia”
- Hay patentes o publicaciones? IP?
- TRL creíbles (punto de partida y punto final)

# Excelencia



## Technology Readiness Levels

**TRL 0:** **Idea.** Unproven concept, no testing has been performed.

**TRL 1:** **Basic research.** Principles postulated and observed but no experimental proof available.

**TRL 2:** **Technology formulation.** Concept and application have been formulated.

**TRL 3:** **Applied research.** First laboratory tests completed; proof of concept.

**TRL 4:** **Small scale prototype** built in a laboratory environment ("ugly" prototype).

**TRL 5:** **Large scale prototype** tested in intended environment.

**TRL 6:** **Prototype system** tested in intended environment close to expected performance.

**TRL 7:** **Demonstration system** operating in operational environment at pre-commercial scale.

**TRL 8:** **First of a kind commercial system.** Manufacturing issues solved.

**TRL 9:** **Full commercial application,** technology available for consumers.

## HOW TO DEFINE YOUR TRL

### Example from pharmaceutical industries

It is important to emphasize that the **TRL scale is self-declared** and it may differ from sector to sector. Find the pharma sectorial application of TRL scale applied to drug discovery process.

It spans the whole innovation process, from basic research activities and preclinical studies (TRL1-4), over investigational new drug application (TRL5), to clinical trials (TRL6-8) and product launch (TRL9).

- + TRL 1 Findings reviewed
- + TRL 2 Research idea
- + TRL 3 Design proof of concept
- + TRL 4 Demonstrate proof of concept
- + TRL 5 Pilot drug produced
- + TRL 6 Phase 1 clinical trials
- + TRL 7 Phase 2 clinical trials
- + TRL 8 New drug registration
- + TRL 9 Drug distributed and marketed

# Excelencia

**Proposal template Part B: technical description**

**TITLE OF THE PROPOSAL**

[This document is tagged. Do not delete the tags; they are needed for processing.] #@APP-FORM-HERIAIA#@

**List of participants**

Participant No. *	Participant organisation name	Country
1 (Coordinator)		
2		
3		
...		

1. **Excellence** #@REL-EVA-RE@#

1.1 **Objectives and ambition** #@PRJ-OBJ-PO@#

Insert here text for your proposal

#\$PRJ-OBJ-PO\$#

1.2 **Methodology** #@CON-MET-CM@# #@COM-PLE-PR@#

Insert here text for your proposal

#\$CON-MET-CM\$# #\$COM-PLE-PR\$# #\$REL-EVA-RE\$#

## Methodology

- Incluir estadísticas de los EECC que vamos a realizar
- “Do not significant harm” – ejemplos de cómo cumplimos. Intentar no copiar-pegar normativa.
- AI/modelos computacionales – AI para decisiones clínicas = Medical device, [Requirements of Trustworthy AI](#) (Informe CE)
- Interdisciplinaridad
- Ciencias sociales (SSH)
- Dimensión sexo y genero transversal -> Metodología (incidencia, investigación) – impacto (comunicación eficiente) – implementación (tareas concretas)
- Open Science – no copy-paste indicaciones de CE
- Research management plan – aunque sea un deliverable (M6) incluir información, hay procedimientos en la institución?

# Excelencia



## Open Science across the programme

Open  
Science

Mainstreaming of open science practices for improved quality and efficiency of R&I, and active engagement of society


**Mandatory immediate Open Access to publications:** beneficiaries must retain sufficient IPRs to comply with open access requirements;

**Data sharing as 'open as possible, as closed as necessary':** mandatory Data Management Plan for FAIR (Findable, Accessible, Interoperable, Reusable) research data

- Work Programmes may incentivize or oblige to adhere to **open science practices** such as involvement of citizens, or to use the **European Open Science Cloud**
- Assessment of open science practices through the **award criteria** for proposal evaluation
- Dedicated support to **open science policy actions**
- **Open Research Europe** publishing platform



## Research Data Management



# Impacto

## 2. Impact @@IMP-ATT-IA&U 2.1 Project's pathways towards impact

Insert here text for your proposal


## 2.2 Measures to maximise impact - Dissemination, exploitation and communication @@COM-DIS-VIS-CDV@#

Insert here text for your proposal

##COM-DIS-VIS-CDV##


## Project's pathways towards impact

- Impactos sociales, económicos y científicos (¡cuantificados!),
- Outcomes – Topic
- Impacts – Destinos
- Si es posible contribución a las políticas – Introducción a destinos
- Barreras para conseguir outcomes/impactos – medidas de mitigación y comprobación



European  
Commission

# Impacto



# Impacto

## 2. Impact @@IMP-AG1&#U

### 2.1 Project's pathways towards impact

Insert here text for your proposal


### 2.2 Measures to maximise impact - Dissemination, exploitation and communication @@COM-DIS-VIS-CDV@@#

Insert here text for your proposal

#\$COM-DIS-VIS-CDV\$#

## Measures to maximise impact

- Mensaje y canales adaptado a las distintos targets
- Innovación: explotar > diseminar resultados



# Impacto

## KEY ELEMENT OF THE IMPACT SECTION

### SPECIFIC NEEDS

*What are the specific needs that triggered this project?*

Insert here text for your proposal

### EXPECTED RESULTS

*What do you expect to generate by the end of the project?*

Insert here text for your proposal

### D & E & C MEASURES

*What dissemination, exploitation and communication measures will you apply to the results?*

Insert here text for your proposal

### TARGET GROUPS

*Who will use or further up-take the results of the project? Who will benefit from the results of the project?*

Insert here text for your proposal

### OUTCOMES

*What change do you expect to see after successful dissemination and exploitation of project results to the target group(s)?*

Insert here text for your proposal

### IMPACTS

*What are the expected wider scientific, economic and societal effects of the project contributing to the expected impacts outlined in the respective destination in the work programme?*

Insert here text for your proposal

# Implementación

3. Quality and efficiency of the implementation @@QUA-LIT-QL@# @@WRK-PLA-WP@#

3.1 Work plan and resources

Insert here text for your proposal


3.2 Capacity of participants and consortium as a whole @@CON-SOR-CS@# @@PRJ-MGT-PM@#

Insert here text for your proposal

complete

## Work plan and resources

- Cada socio tiene que aportar algo al consorcio pero no participar solo en 1 WP



## Capacity of participants and consortium as a whole

- Hay publicaciones previas o proyectos conjuntos que demuestren la solidez del consorcio?
- Estructuras de gestión y toma de decisiones
- Podemos incluir Boards de ética, EECC, IA, explotación,..

¡Gracias por  
su atención!



Marta Marín  
[marta.marin@fecyt.es](mailto:marta.marin@fecyt.es)